Oruka CEO Klein Says Company Could Face Transformative Year
"We are very pleased with the progress of both our co-lead programs as we advance into what could be a transformative year for our company," said Lawrence Klein, Chief Executive Officer of Oruka. "Given strong site engagement and enthusiasm, EVERLAST-A completed enrollment in December 2025, enabling us to bring our initial data release into the second quarter of 2026. Meanwhile, we are excited to be starting our Phase 2 efforts with ORKA-002, which we believe could be a very impactful program in psoriatic disease and HS."
